Phase 2 setanaxib + pembrolizumab in recurrent/metastatic SCCHN
Squamous Cell Carcinoma of Head and Neck
Enrolment: 55 · Results not recorded
Loading the evidence…
Drug · NADPH oxidase 1/4 (NOX1/NOX4) inhibitor (no ChEMBL mechanism record).
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Squamous Cell Carcinoma of Head and Neck
Enrolment: 55 · Results not recorded
Idiopathic Pulmonary Fibrosis
Enrolment: 58 · Results not recorded
Primary Biliary Cirrhosis
Enrolment: 111 · Results not recorded
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Enrolment: 136 · Results not recorded
Primary Biliary Cholangitis · Liver Stiffness
Enrolment: 76 · Results not recorded
Alport Syndrome
Enrolment: 20 · Results not recorded
Phase 1
Enrolment: 64 · Results not recorded
Phase 1
Enrolment: 15 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Non-invasive tibial compression knee injury producing anterior cruciate ligament rupture by bony avulsion, delivered as a single dynamic overload at 1 mm/s to a target compressive force of 14 N, as a model of post-traumatic osteoarthritis; simulated injury in primary human chondrocytes using IL-1beta, TNF-alpha or TGF-beta at 10 ng/ml
Nox4 activity, mRNA and protein fell acutely within the first 24 h after joint injury in both human chondrocytes and mouse knees, then rose above baseline with a peak at 48 h and elevation persisting to 72 h. Daily GKT137831 for 7 days after injury prevented the significant fall in subchondral bone…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.